Jatinder Lamba

Jatinder Lamba, Ph.D., M.Sc.

Professor And Graduate Coordinator

Department: Pharmacotherapy & Translational Research
Business Phone: (352) 273-6425
Business Email: jlamba@cop.ufl.edu

About Jatinder Lamba

Dr. Jatinder Lamba is currently Professor in the Department of Pharmacotherapy and Translational Research. She did her post-doctoral training at St. Jude Children’s Research Hospital in Memphis, Tennessee. Prior to joining University of Florida, she was an Associate Professor at University of Minnesota, Department of Experimental and Clinical Pharmacology, College of Pharmacy and the Director of the Pathway driven Pharmacogenomics; University of Minnesota Alliance (PUMA) Institute of Personalized Medicine.

Dr Lamba’s research is focused on identification, characterization and clinical validation of genomic/epigenomic markers predictive of therapeutic outcome in cancer patients. This research spans from preclinical basic research comprising the discovery phase utilizing cell line model systems to translational/clinical phase in patient populations from multi-institute clinical trials. The long-term goal of her research is to move pharmacogenetic testing into the clinical setting to improve safety and efficacy of drug therapy. Dr. Lamba’s research on pharmacogenomics of anti-leukemic agents has been funded by NIH/NCI since 2008. Specifically, her current NCI funded R01 focuses on pharmacogenomics/ epigenomics of cytarabine (ara-C), a nucleoside analog that is the backbone of anti-leukemia chemotherapy in pediatric AML patients. Her group is working on developing algorithms to incorporate pharmacogenomics/epigenomic markers with other prognostic factors to advance precision medicine in oncology. Identification of such patients upfront will provide opportunity to tailor the initial chemotherapy to achieve maximum benefit.

Dr. Lamba’s lab is the first one to identify genetic polymorphisms in CD33 gene that are predictive of response to CD33 targeted agents in AML. These results hold promise in utilizing preemptive genotype to select patients most likely to benefit from CD33-directed therapy such as gemtuzumab ozogamicin in treating AML. Previous work on CD33 genomics was funded by NCI and more in-depth characterization of CD33 as AML therapeutic target is funded by a recent award from leukemia Lymphoma Society.

Given a critical gap of our understanding in metabolic dysregulation in AML, Dr. Lamba’s group is focused understanding the metabolomics differences and biomarkers of prognostic significance in pediatric AML. Dr. Lamba’s recent work is focused towards utilizing transcriptomics to build and refine leukemic stem cell signatures and AML drug response signatures of prognostic and predictive value in AML.

Dr. Lamba has served as chair of Pharmacogenomics SIG at AACP (2013) and is currently vice-chair of Pharmacogenomics focus group with AAPS. She has served as a grant reviewer for numerous NIH study sections and has reviewed grants for international agencies as Italian Ministry of Health. She has published more than 90 research articles in peer-reviewed journals and is on the editorial boards of Leukemia and Lymphoma, Pharmacogenomics and Frontiers in Pharmacogenomics and genomics, JCMM. Dr. Lamba is currently Professor in College of Pharmacy and is also Graduate Program coordinator for PTR department. Dr. Lamba is very committed towards training of future generation of scientist. She has trained 6 Ph. D students, 5 Post-doctoral fellows several Pharm D students and 3 hematology-oncology fellows and several under-graduate students including minority and underrepresented students.

Research Profile

Open Researcher and Contributor ID (ORCID)

0000-0003-0411-0007

Publications

2021
Building a precision oncology workforce by multidisciplinary and case-based learning.
BMC medical education. 21(1) [DOI] 10.1186/s12909-021-02500-6. [PMID] 33499867.
2021
DNA Methylation-Based Epigenetic Repression of SLC22A4 Promotes Resistance to Cytarabine in Acute Myeloid Leukemia.
Clinical and translational science. 14(1):137-142 [DOI] 10.1111/cts.12861. [PMID] 32905646.
2021
Novel CD33 antibodies unravel localization, biology and therapeutic implications of CD33 isoforms.
Future oncology (London, England). 17(3):263-277 [DOI] 10.2217/fon-2020-0746. [PMID] 33356566.
2021
Potential Risk Factors Associated With Graft Failure of Haploidentical Hematopoietic Stem Cell Transplantation in Children With Sickle Cell Disease.
Journal of pediatric hematology/oncology. 43(4):e583-e586 [DOI] 10.1097/MPH.0000000000001873. [PMID] 32604335.
2021
SIRT1 Gene SNP rs932658 Is Associated With Medication-Related Osteonecrosis of the Jaw.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 36(2):347-356 [DOI] 10.1002/jbmr.4185. [PMID] 32967053.
2020
A six-gene leukemic stem cell score identifies high risk pediatric acute myeloid leukemia.
Leukemia. 34(3):735-745 [DOI] 10.1038/s41375-019-0604-8. [PMID] 31645648.
2020
Correction: A six-gene leukemic stem cell score identifies high risk pediatric acute myeloid leukemia.
Leukemia. 34(10):2821-2821 [DOI] 10.1038/s41375-020-0822-0. [PMID] 32300185.
2020
DNA Methylation Clusters and Their Relation to Cytogenetic Features in Pediatric AML.
Cancers. 12(10) [DOI] 10.3390/cancers12103024. [PMID] 33080932.
2020
Functional Dependency Analysis Identifies Potential Druggable Targets in Acute Myeloid Leukemia.
Cancers. 12(12) [DOI] 10.3390/cancers12123710. [PMID] 33321907.
2020
Impact of CD33 and ABCB1 single nucleotide polymorphisms in patients with acute myeloid leukemia and advanced myeloid malignancies treated with decitabine plus gemtuzumab ozogamicin.
American journal of hematology. 95(9):E225-E228 [DOI] 10.1002/ajh.25854. [PMID] 32356320.
2019
A genomics-informed computational biology platform prospectively predicts treatment responses in AML and MDS patients.
Blood advances. 3(12):1837-1847 [DOI] 10.1182/bloodadvances.2018028316. [PMID] 31208955.
2019
ABCB1 SNP predicts outcome in patients with acute myeloid leukemia treated with Gemtuzumab ozogamicin: a report from Children’s Oncology Group AAML0531 Trial.
Blood cancer journal. 9(6) [DOI] 10.1038/s41408-019-0211-y. [PMID] 31113932.
2019
CCGG deletion (rs201074739) in CD33 results in premature termination codon and complete loss of CD33 expression: another key variant with potential impact on response to CD33-directed agents.
Leukemia & lymphoma. 60(9):2287-2290 [DOI] 10.1080/10428194.2019.1569232. [PMID] 30721105.
2019
CD33_PGx6_Score Predicts Gemtuzumab Ozogamicin Response in Childhood Acute Myeloid Leukemia: A Report From the Children’s Oncology Group.
JCO precision oncology. 3 [DOI] 10.1200/PO.18.00387. [PMID] 32914031.
2019
MicroRNAs Mediated Regulation of Expression of Nucleoside Analog Pathway Genes in Acute Myeloid Leukemia.
Genes. 10(4) [DOI] 10.3390/genes10040319. [PMID] 31022985.
2019
Pharmacogenomics of osteonecrosis of the jaw.
Bone. 124:75-82 [DOI] 10.1016/j.bone.2019.04.010. [PMID] 31022475.
2019
Systematic Dissection of the Metabolic-Apoptotic Interface in AML Reveals Heme Biosynthesis to Be a Regulator of Drug Sensitivity.
Cell metabolism. 29(5):1217-1231.e7 [DOI] 10.1016/j.cmet.2019.01.011. [PMID] 30773463.
2018
CD33 splicing SNP regulates expression levels of CD33 in normal regenerating monocytes in AML patients.
Leukemia & lymphoma. 59(9):2250-2253 [DOI] 10.1080/10428194.2017.1421756. [PMID] 29320902.
2018
Comprehensive Ara-C SNP score predicts leukemic cell intracellular ara-CTP levels in pediatric acute myeloid leukemia patients.
Pharmacogenomics. 19(14):1101-1110 [DOI] 10.2217/pgs-2018-0086. [PMID] 30088438.
2018
Correction: Integrated epigenetic and genetic analysis identifies markers of prognostic significance in pediatric acute myeloid leukemia.
Oncotarget. 9(54) [DOI] 10.18632/oncotarget.25792. [PMID] 30101002.
2018
Distinct Metabolic features differentiating FLT3-ITD AML from FLT3-WT childhood Acute Myeloid Leukemia.
Scientific reports. 8(1) [DOI] 10.1038/s41598-018-23863-9. [PMID] 29615816.
2018
Gemtuzumab ozogamicin for treatment of newly diagnosed CD33-positive acute myeloid leukemia.
Future oncology (London, England). 14(30):3199-3213 [DOI] 10.2217/fon-2018-0325. [PMID] 30039981.
2018
Genome-wide association analysis identifies SNPs predictive of in vitro leukemic cell sensitivity to cytarabine in pediatric AML.
Oncotarget. 9(79):34859-34875 [DOI] 10.18632/oncotarget.26163. [PMID] 30405880.
2017
CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children’s Oncology Group Trial AAML0531.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 35(23):2674-2682 [DOI] 10.1200/JCO.2016.71.2513. [PMID] 28644774.
2017
Computational drug treatment simulations on projections of dysregulated protein networks derived from the myelodysplastic mutanome match clinical response in patients.
Leukemia research. 52:1-7 [DOI] 10.1016/j.leukres.2016.11.004. [PMID] 27855285.
2016
CC-PROMISE effectively integrates two forms of molecular data with multiple biologically related endpoints.
BMC bioinformatics. 17(Suppl 13) [PMID] 27766934.
View on: PubMed
2016
Clinical significance of in vivo cytarabine-induced gene expression signature in AML.
Leukemia & lymphoma. 57(4):909-20 [DOI] 10.3109/10428194.2015.1086918. [PMID] 26366682.
2016
Expression and functional characterization of CD33 transcript variants in human acute myeloid leukemia.
Oncotarget. 7(28):43281-43294 [DOI] 10.18632/oncotarget.9674. [PMID] 27248327.
2016
Genome-Wide Study of Response to Platinum, Taxane, and Combination Therapy in Ovarian Cancer: In vitro Phenotypes, Inherited Variation, and Disease Recurrence.
Frontiers in genetics. 7 [DOI] 10.3389/fgene.2016.00037. [PMID] 27047539.
2015
Cytochrome P450 2B6*5 Increases Relapse after Cyclophosphamide-Containing Conditioning and Autologous Transplantation for Lymphoma.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 21(5):944-8 [DOI] 10.1016/j.bbmt.2015.02.001. [PMID] 25677220.
2015
Folate metabolic pathway single nucleotide polymorphisms: a predictive pharmacogenetic marker of methotrexate response in Indian (Asian) patients with rheumatoid arthritis.
Pharmacogenomics. 16(18):2019-34 [DOI] 10.2217/pgs.15.145. [PMID] 26616421.
2015
Genome-wide association analysis identified splicing single nucleotide polymorphism in CFLAR predictive of triptolide chemo-sensitivity.
BMC genomics. 16 [DOI] 10.1186/s12864-015-1614-1. [PMID] 26121980.
2015
MicroRNA-mRNA Pairs Associated with Outcome in AML: From In Vitro Cell-Based Studies to AML Patients.
Frontiers in pharmacology. 6 [DOI] 10.3389/fphar.2015.00324. [PMID] 26858643.
2014
A therapeutic trial of decitabine and vorinostat in combination with chemotherapy for relapsed/refractory acute lymphoblastic leukemia.
American journal of hematology. 89(9):889-95 [DOI] 10.1002/ajh.23778. [PMID] 24891274.
2014
Genetic variation in platinating agent and taxane pathway genes as predictors of outcome and toxicity in advanced non-small-cell lung cancer.
Pharmacogenomics. 15(12):1565-74 [DOI] 10.2217/pgs.14.107. [PMID] 25340731.
2014
Identification of suitable reference genes for hepatic microRNA quantitation.
BMC research notes. 7 [DOI] 10.1186/1756-0500-7-129. [PMID] 24606728.
2014
PharmGKB summary: gemcitabine pathway.
Pharmacogenetics and genomics. 24(11):564-74 [DOI] 10.1097/FPC.0000000000000086. [PMID] 25162786.
2014
SLC28A3 genotype and gemcitabine rate of infusion affect dFdCTP metabolite disposition in patients with solid tumours.
British journal of cancer. 110(2):304-12 [DOI] 10.1038/bjc.2013.738. [PMID] 24300978.
2013
Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy.
Pharmacogenomics. 14(1):35-45 [DOI] 10.2217/pgs.12.180. [PMID] 23252947.
2013
Clinical significance of CD33 nonsynonymous single-nucleotide polymorphisms in pediatric patients with acute myeloid leukemia treated with gemtuzumab-ozogamicin-containing chemotherapy.
Clinical cancer research : an official journal of the American Association for Cancer Research. 19(6):1620-7 [DOI] 10.1158/1078-0432.CCR-12-3115. [PMID] 23444229.
2013
Comprehensive genetic analysis of cytarabine sensitivity in a cell-based model identifies polymorphisms associated with outcome in AML patients.
Blood. 121(21):4366-76 [DOI] 10.1182/blood-2012-10-464149. [PMID] 23538338.
2013
RRM1 and RRM2 pharmacogenetics: association with phenotypes in HapMap cell lines and acute myeloid leukemia patients.
Pharmacogenomics. 14(12):1449-66 [DOI] 10.2217/pgs.13.131. [PMID] 24024897.
2013
Valproic acid pathway: pharmacokinetics and pharmacodynamics.
Pharmacogenetics and genomics. 23(4):236-41 [DOI] 10.1097/FPC.0b013e32835ea0b2. [PMID] 23407051.
2012
Assessment of healthcare students’ views on pharmacogenomics at the University of Minnesota.
Pharmacogenomics. 13(13):1537-45 [DOI] 10.2217/pgs.12.139. [PMID] 23057552.
2012
Cytotoxic purine nucleoside analogues bind to A1, A2A, and A3 adenosine receptors.
Naunyn-Schmiedeberg's archives of pharmacology. 385(5):519-25 [DOI] 10.1007/s00210-011-0719-6. [PMID] 22249336.
2012
Exploration of CYP450 and drug transporter genotypes and correlations with nevirapine exposure in Malawians.
Pharmacogenomics. 13(1):113-21 [DOI] 10.2217/pgs.11.132. [PMID] 22111602.
2012
Germline predictors of androgen deprivation therapy response in advanced prostate cancer.
Mayo Clinic proceedings. 87(3):240-6 [DOI] 10.1016/j.mayocp.2011.09.009. [PMID] 22386179.
2012
Intestinal CYP3A4 and midazolam disposition in vivo associate with VDR polymorphisms and show seasonal variation.
Biochemical pharmacology. 84(1):104-12 [DOI] 10.1016/j.bcp.2012.03.017. [PMID] 22484315.
2012
Pathway-based pharmacogenomics of gemcitabine pharmacokinetics in patients with solid tumors.
Pharmacogenomics. 13(9):1009-21 [DOI] 10.2217/pgs.12.81. [PMID] 22838949.
2012
PharmGKB summary: zidovudine pathway.
Pharmacogenetics and genomics. 22(12):891-4 [DOI] 10.1097/FPC.0b013e32835879a8. [PMID] 22960662.
2012
Using PharmGKB to train text mining approaches for identifying potential gene targets for pharmacogenomic studies.
Journal of biomedical informatics. 45(5):862-9 [DOI] 10.1016/j.jbi.2012.04.007. [PMID] 22564551.
2011
CYP3A4 mediates growth of estrogen receptor-positive breast cancer cells in part by inducing nuclear translocation of phospho-Stat3 through biosynthesis of (±)-14,15-epoxyeicosatrienoic acid (EET).
The Journal of biological chemistry. 286(20):17543-59 [DOI] 10.1074/jbc.M110.198515. [PMID] 21402692.
2011
Genetic variants in cytosolic 5′-nucleotidase II are associated with its expression and cytarabine sensitivity in HapMap cell lines and in patients with acute myeloid leukemia.
The Journal of pharmacology and experimental therapeutics. 339(1):9-23 [DOI] 10.1124/jpet.111.182873. [PMID] 21712425.
2011
Identification of predictive markers of cytarabine response in AML by integrative analysis of gene-expression profiles with multiple phenotypes.
Pharmacogenomics. 12(3):327-39 [DOI] 10.2217/pgs.10.191. [PMID] 21449673.
2011
Impact of genetic variation in FKBP5 on clinical response in pediatric acute myeloid leukemia patients: a pilot study.
Leukemia. 25(8):1354-6 [DOI] 10.1038/leu.2011.74. [PMID] 21483441.
2011
Pharmacogenomics of cytarabine in childhood leukemia.
Pharmacogenomics. 12(12):1629-32 [DOI] 10.2217/pgs.11.148. [PMID] 22118048.
2010
CYP2C9*1B promoter polymorphisms, in linkage with CYP2C19*2, affect phenytoin autoinduction of clearance and maintenance dose.
The Journal of pharmacology and experimental therapeutics. 332(2):599-611 [DOI] 10.1124/jpet.109.161026. [PMID] 19855097.
2010
PharmGKB summary: very important pharmacogene information for CYP2B6.
Pharmacogenetics and genomics. 20(8):520-3 [PMID] 20648701.
View on: PubMed
2009
Coding polymorphisms in CD33 and response to gemtuzumab ozogamicin in pediatric patients with AML: a pilot study.
Leukemia. 23(2):402-4 [DOI] 10.1038/leu.2008.185. [PMID] 18615103.
2009
Genetic factors influencing cytarabine therapy.
Pharmacogenomics. 10(10):1657-74 [DOI] 10.2217/pgs.09.118. [PMID] 19842938.
2009
Population-specific genetic variants important in susceptibility to cytarabine arabinoside cytotoxicity.
Blood. 113(10):2145-53 [DOI] 10.1182/blood-2008-05-154302. [PMID] 19109566.
2009
PROMISE: a tool to identify genomic features with a specific biologically interesting pattern of associations with multiple endpoint variables.
Bioinformatics (Oxford, England). 25(16):2013-9 [DOI] 10.1093/bioinformatics/btp357. [PMID] 19528086.
2008
Association of breast cancer resistance protein/ABCG2 phenotypes and novel promoter and intron 1 single nucleotide polymorphisms.
Drug metabolism and disposition: the biological fate of chemicals. 36(4):780-95 [DOI] 10.1124/dmd.107.018366. [PMID] 18180275.
2008
Novel single nucleotide polymorphisms in the promoter and intron 1 of human pregnane X receptor/NR1I2 and their association with CYP3A4 expression.
Drug metabolism and disposition: the biological fate of chemicals. 36(1):169-81 [PMID] 17925385.
View on: PubMed
2008
Pharmacogenetics of the constitutive androstane receptor.
Pharmacogenomics. 9(1):71-83 [PMID] 18154449.
View on: PubMed
2008
The influence of CYP3A5 genotype on dexamethasone induction of CYP3A activity in African Americans.
Drug metabolism and disposition: the biological fate of chemicals. 36(8):1465-9 [DOI] 10.1124/dmd.107.020065. [PMID] 18490434.
2007
Genetic nondiscrimination legislation: a critical prerequisite for pharmacogenomics data sharing.
Pharmacogenomics. 8(5) [PMID] 17465717.
View on: PubMed
2007
Pharmacogenetics of deoxycytidine kinase: identification and characterization of novel genetic variants.
The Journal of pharmacology and experimental therapeutics. 323(3):935-45 [PMID] 17855478.
View on: PubMed
2006
Enzyme-mediated protein haptenation of dapsone and sulfamethoxazole in human keratinocytes: I. Expression and role of cytochromes P450.
The Journal of pharmacology and experimental therapeutics. 319(1):488-96 [PMID] 16857728.
View on: PubMed
2006
G2677T and C3435T genotype and haplotype are associated with hepatic ABCB1 (MDR1) expression.
Journal of clinical pharmacology. 46(3):373-9 [PMID] 16490813.
View on: PubMed
2006
Increased CYP3A4 copy number in TONG/HCC cells but not in DNA from other humans.
Pharmacogenetics and genomics. 16(6):415-27 [PMID] 16708050.
View on: PubMed
2006
MDR1 genotype is associated with hepatic cytochrome P450 3A4 basal and induction phenotype.
Clinical pharmacology and therapeutics. 79(4):325-38 [PMID] 16580901.
View on: PubMed
2005
Genetic variants of PXR (NR1I2) and CAR (NR1I3) and their implications in drug metabolism and pharmacogenetics.
Current drug metabolism. 6(4):369-83 [PMID] 16101575.
View on: PubMed
2005
Sequential analysis of tacrolimus dosing in adult lung transplant patients with ABCB1 haplotypes.
Journal of clinical pharmacology. 45(4):404-10 [PMID] 15778421.
View on: PubMed
2005
The impact of pharmacogenomic factors on acute persistent rejection in adult lung transplant patients.
Transplant immunology. 14(1):37-42 [PMID] 15814280.
View on: PubMed
2004
Expression of constitutive androstane receptor splice variants in human tissues and their functional consequences.
The Journal of pharmacology and experimental therapeutics. 311(2):811-21 [PMID] 15194709.
View on: PubMed
2004
PharmGKB update: II. CYP3A5, cytochrome P450, family 3, subfamily A, polypeptide 5.
Pharmacological reviews. 56(2) [PMID] 15169924.
View on: PubMed
2004
PXR (NR1I2): splice variants in human tissues, including brain, and identification of neurosteroids and nicotine as PXR activators.
Toxicology and applied pharmacology. 199(3):251-65 [PMID] 15364541.
View on: PubMed
2004
Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism.
Journal of clinical pharmacology. 44(2):135-40 [PMID] 14747421.
View on: PubMed
2004
The impact of pharmacogenomic factors on steroid dependency in pediatric heart transplant patients using logistic regression analysis.
Pediatric transplantation. 8(6):551-7 [PMID] 15598322.
View on: PubMed
2003
CYP3A5 genotype predicts renal CYP3A activity and blood pressure in healthy adults.
Journal of applied physiology (Bethesda, Md. : 1985). 95(3):1297-300 [PMID] 12754175.
View on: PubMed
2003
Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression.
The Journal of pharmacology and experimental therapeutics. 307(3):906-22 [PMID] 14551287.
View on: PubMed
2003
Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine.
Pharmacogenetics. 13(1):19-28 [PMID] 12544509.
View on: PubMed
2003
Nonsense mediated decay downregulates conserved alternatively spliced ABCC4 transcripts bearing nonsense codons.
Human molecular genetics. 12(2):99-109 [PMID] 12499391.
View on: PubMed
2003
The CYP3A4*1B variant is related to the onset of puberty, a known risk factor for the development of breast cancer.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 12(4):327-31 [PMID] 12692107.
View on: PubMed
2002
Common allelic variants of cytochrome P4503A4 and their prevalence in different populations.
Pharmacogenetics. 12(2):121-32 [PMID] 11875366.
View on: PubMed
2002
Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 20(17):3683-90 [PMID] 12202670.
View on: PubMed
2002
Genetic contribution to variable human CYP3A-mediated metabolism.
Advanced drug delivery reviews. 54(10):1271-94 [PMID] 12406645.
View on: PubMed
2002
The MDR1 polymorphisms at exons 21 and 26 predict steroid weaning in pediatric heart transplant patients.
Human immunology. 63(9):765-70 [PMID] 12175731.
View on: PubMed
2001
Disrupted bile acid homeostasis reveals an unexpected interaction among nuclear hormone receptors, transporters, and cytochrome P450.
The Journal of biological chemistry. 276(42):39411-8 [PMID] 11509573.
View on: PubMed
2001
Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression.
Nature genetics. 27(4):383-91 [PMID] 11279519.
View on: PubMed
2000
CYP2C19 genetic mutations in North Indians.
Clinical pharmacology and therapeutics. 68(3):328-35 [PMID] 11014415.
View on: PubMed
1998
Genetic polymorphism of CYP2D6 in North Indian subjects.
European journal of clinical pharmacology. 54(9-10):787-91 [PMID] 9923585.
View on: PubMed

Grants

Jul 2021 ACTIVE
Transcriptomic and pharmacogenetic scores to guide therapy in pediatric AML
Role: Principal Investigator
Funding: AMER CANCER SOC
Sep 2020 ACTIVE
AFPE Fellowship: Rho Chi -AFPE Graduate Fellowship
Role: Other
Funding: AMER FOU FOR PHARM EDU
Sep 2020 ACTIVE
Pharmacogenomic Drivers of Efficacy in Anti-CD33 Immunotherapeutic Treatment Strategies
Role: Other
Funding: AMER FOU FOR PHARM EDU
Aug 2020 ACTIVE
Pharmacokinetics and Pharmacogenomics of Pediatric Chemotherapeutics
Role: Principal Investigator
Funding: UNIV OF CALIFORNIA SAN FRANCISCO via CANCER LEAGUE
Jan 2020 ACTIVE
Asparaginase Premedication, Hypersensitivity, and Therapeutic Drug Monitoring in Pediatric Patients with Acute Lymphoblastic Leukemia or Lymphoma
Role: Principal Investigator
Funding: CHILDRENS HOSP OF ORANGE COUNTY via PEDIATRIC SUBSPECIALTY FACULTY
Jul 2019 ACTIVE
Personalizing CD33-directed Immunotherapy for Pediatric AML
Role: Principal Investigator
Funding: LEUKEMIA & LYMPHOMA SOC
Jul 2019 – Jun 2020
Personalizing CD33-directed immunotherapy for pediatric AML
Role: Principal Investigator
Funding: CHILDRENS ONCOLOGY GROUP via ST BALDRICKS FOUNDATION
Apr 2019 ACTIVE
Pharmacogenomics and Toxicities of Thiotepa, Busulfan and Fludarabine in Pediatric HSCT Recipients
Role: Principal Investigator
Funding: FL DEPT OF HLTH LIVE LIKE BELLA
Jun 2018 ACTIVE
OR-DRPD-ROD2018: Development of Leukemia-Oncotype Prototype CARS (Cytarabine AML Response Score) for Prediction of Relapse Risk in AML
Role: Principal Investigator
Funding: UF RESEARCH
Feb 2018 – Jan 2019
Impact of CD33 Genetics on Clinical Outcome in Pediatric AML Patients Treated on AAML0531 Clinical Trial
Role: Principal Investigator
Funding: CHILDRENS ONCOLOGY GROUP via ST BALDRICKS FOUNDATION
Dec 2016 – Jan 2020
Multiple Sponsors
Role: Principal Investigator
Funding: MULTIPLE SPONSORS
Jan 2015 – Jan 2016
DNA ISOLATION/GENOTYPING COLLABORATION
Role: Principal Investigator
Funding: UNIV OF MINNESOTA
Sep 2014 – Apr 2020
Pharmacogenomics of Ara-C in AML
Role: Principal Investigator
Funding: NATL INST OF HLTH NCI
Jul 2014 – Dec 2015
Impact of genetic variation on response to GO therapy in COG-AML clinical trials
Role: Principal Investigator
Funding: NATL INST OF HLTH NCI

Education

Ph.D.
2000 · Postgraduate Institute of Medical Education and Research
M.Sc.
1994 · Postgraduate Institute of Medical Education and Research
B.Sc.
1992 · Panjab University

Teaching Profile

Courses Taught
2015-2021
PHA6938 Research Seminar
2015-2021
PHA7979 Advanced Research
2016-2018,2020-2021
PHA6910 Supervised Research
2018-2020
PHA6427 Pharmacogenetics of Drug Metabolism
2015-2021
PHA7980 Research for Doctoral Dissertation
2019-2021
PHA6935 Selected Topics in Pharmacy
2020-2021
PHA6894 Introduction to Graduate Studies
2016-2017,2019-2021
PHA6971 Research for Master’s Thesis
2019
PHA7939 Journal Colloquy in Pharmacodynamics
2016-2018
PHA5782C Patient Care 2
2017-2018
PHA5787C Pt Care 5: Endo
2015-2016
PHA5113 Personalized Medicine
2015
PHA5907 Research in Phar Prac

Contact Details

Phones:
Business:
(352) 273-6425
Emails:
Business:
jlamba@cop.ufl.edu

News Stories

Lamba’s Lab (Coming Soon)